このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Active Search for Pediatric HIV/AIDS (ASPA) (ASPA)

2017年1月22日 更新者:Dr Yumo, Habakkuk Azinyui、Research for Development International
The Active Search for Pediatric HIV/AIDS (ASPA) aims at assessing the acceptability, feasibility and effectiveness of the targeted provider-initiated-testing and counseling (tPITC) in comparison with the blanket provider-initiated-testing and counseling (bPITC) among children and adolescents in Cameroon. The new knowledge generated will inform programming of more suitable strategies to identify HIV-infected children and adolescents and this will contribute to reducing the current global gap in HIV treatment among this subpopulation group.

調査の概要

詳細な説明

Introduction: Globally in 2014, the antiretroviral therapy (ART) coverage rate amongst children was 32% against 41% in adults, and in Cameroon this gap was even wider (10.4% % vs 28%). Identifying and linking children to care are key barriers to effective expansion of pediatric ART in resources-limited settings. To identify HIV-infected children and enroll positive cases in care, the World Health Organization (WHO) recommended in 2007, the provider-initiated-testing and counseling (PITC) strategy. The blanket PITC (bPITC), whereby all children consulting in the health facility have to be screened for HIV requires a lot of resources in terms of HIV testing kits and supplies in addition to the increased workload on the already overburden health personnel in resource-limited settings. Conversely, the targeted PITC approach (tPITC) where children born to HIV-infected parents are offered HIV testing and counseling seems more feasible and effective. The primary objective of this study is to assess the effectiveness of tPITC in comparison with bPITC in case detection of HIV-infected children and adolescents. The secondary objective is to assess the acceptability and feasibility of tPITC in comparison with bPTIC among children and adolescents in Cameroon.

Methods:

Design: The investigator will conduct in 3 health facilities a non-randomized controlled pragmatic trial comparing the effectiveness of the targeted (intervention arm) against the blanket PITC (control arm) in case finding and linkage of HIV-infected children and adolescents in HIV treatment.

Study population: For the intervention arm, the study population will be children and adolescents between 6 weeks to 19 years born to HIV-infected parents and the control arm will be children of the same age group seeking care in the hospital irrespective of the motive of consultations.

Procedure: The study will be implemented in the Limbe Regional Hospital (South West Region), the Abong-Mbang District Hospital (East Region) and the Ndop District Hospital (North West Region) in Cameroon for a period of 36 months. Prior to the conduct of the study, health facility staff will be trained in PITC implementation. Testing kits and supplies will be made available to the site. Enrolment in the 2 arms will be done simultaneously till completion of the sample size. The HIV testing and ART eligibility assessment will be done following the national guidelines.

Sample size calculation: Based on the results of the pilot of this targeted PITC, we believe that with its implementation, the yield of newly diagnosed HIV cases amongst children should at least equal the double of the yield the blanket PITC (control arm) in same health facility. Therefore, the investigators have calculated the sample size to detect the minimum effect in the intervention group equal to at least the double of the yield in the control arm. Computing the formula for sample size calculation of 2 independent samples, we obtained a sample size of 435 children per arm. Hence a total sample size of 870 children.

Data collection, management and analysis: Socio-demographic data for children and parents, HIV status and ART eligibility, linkage to care and HIV treatment outcome will be collected using standardized pre-tested questionnaires. A database will be developed on Microsoft Access for data entry. Data entry will be done progressively till the study sample size is attained. Data analysis will be done using SPSS software and findings will be reported using both descriptive and analytical statistics.

Ethical considerations: Parents' informed consent and children' assent will be required for enrollment into the study. The study will obtain an ethical clearance prior to implementation.

Outcome: This study will assess the effectiveness of targeted PITC in case identification and linkage of HIV-infected children to care/treatment. This new knowledge could be used to reduce the current global gap in pediatric and adolescent HIV treatment.

研究の種類

介入

入学 (予想される)

870

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Limbe、カメルーン
        • Limbe Regional Hospital
    • East
      • Abong Mbang、East、カメルーン
        • Abong-Mbang District Hospital
    • North West
      • Ndop、North West、カメルーン
        • Ndop District Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~19年 (子、大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • HIV-infected parents: Parents diagnosed with HIV infection or receiving HIV services in the hospital and consenting to participate will be eligible for enrollment in the study.
  • Parents/guardians seeking care for their children in the hospital: Parents/guardians presenting at the hospital with sick children will be enrolled in the study irrespective of the motive of consultations for their children.
  • Children of HIV infected parents: children of HIV infected parents aged between 6 weeks to 19 years old will be eligible for enrollment in the study. Parents/guardians consent will be required as well as assent of older kids.
  • Children consulting in the hospital: Children aged 6 weeks to 19 years old consulting in the hospital for any reason will be eligible to participate in the study. Parents/guardians consent will be required as well as assent of older kids.
  • HIV infected children: children (6weeks<years<19 years old) enrolled in HIV care in the hospital at least 2 years before the beginning of the project and after this beginning will be enrolled into the study to assess retention into care and factors associated with loss to follow up.
  • Health personnel: Health personnel involved in children's consultations and consenting to participate will be enrolled in the study.

Exclusion Criteria:

  • Refusal to participate: health personnel, parents/guardians, children not willing to participate will be excluded from the study
  • HIV Status: Children with known HIV positive status will be excluded for HIV testing
  • Age: Children below the age of 6 weeks or above 19 years will be excluded from the study
  • Health conditions: parents who are critically ill or mentally unstable will be excluded from the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention arm
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
介入なし:Control arm
The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Yield
時間枠:6 months
Proportion of newly identified HIV cases amongst all children and adolescents eligible for HIV testing 2. Prevalence: proportion of HIV cases amongst children tested
6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Prevalence
時間枠:6 months
Prevalence: proportion of HIV cases amongst children and adolescents tested for HIV
6 months
Linkage
時間枠:6 months
Linkage in care: proportion of pediatric HIV cases linked to care (CD4 testing and/or enrolment on ART)
6 months
Combined effect (tPITC+bPITC)
時間枠:6 months
Combined effect of tPITC and bPITC: Number of children tested positive and initiated on ART in the hospital during the study as compared to historical data.
6 months
Acceptability
時間枠:6 months
HIV testing acceptance rate: proportion of parents who accepted to have their children tested for HIV. The acceptability assesses the attitude of parents/caregivers to opt in for HIV testing of their children.
6 months
feasibility
時間枠:6 months
HIV testing uptake: proportion of children tested amongst all eligible identified through parents in HIV care (for the targeted arm) or amongst all eligible children who visited the hospital (control arm) during the enrolment period. The feasibility outcome variable assesses the capacity of the health facility to routinely test all eligible children
6 months
Retention
時間枠:24 months
Retention in care: proportion of cases still in care 12 and 24 months after enrolment
24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Habakkuk Yumo, MD, MPH、Research for Development International

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年7月1日

一次修了 (実際)

2016年12月1日

研究の完了 (予想される)

2018年12月1日

試験登録日

最初に提出

2016年12月6日

QC基準を満たした最初の提出物

2017年1月15日

最初の投稿 (見積もり)

2017年1月19日

学習記録の更新

投稿された最後の更新 (見積もり)

2017年1月24日

QC基準を満たした最後の更新が送信されました

2017年1月22日

最終確認日

2017年1月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Data can be made available to other researchers through an application addressed to the sponsor (Research for Development International) and this via the Principal Investigator (Dr Yumo Habakkuk).

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する